American Heart Journal
Volume 150, Issue 2 , Pages 189-192 , August 2005

The vulnerable endothelium: Priming the vascular endothelium for thrombosis with unfractionated heparin: Biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial

  • Richard C. Becker, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Richard C. Becker, MD, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC.

Received 30 November 2004 ,Accepted 5 April 2005.

References 

  1. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54
  2. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non–ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89–96
  3. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001;88:877–887
  4. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651–4655
  5. Honda HM, Leitinger N, Frankel M, et al. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol. 1999;19:680–686
  6. Kouretas PC, Kim YD, Cahill PA, et al. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation. 1999;99:1062–1068
  7. Yokokawa K, Tahara H, Kohno M, et al. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest. 1993;92:2080–2085
  8. Felzen B, Berke G, Gardner P, et al. Involvement of the IP3 cascade in the damage to guinea-pig ventricular myocytes induced by cytotoxic T lymphocytes. Eur J Physiol. 1997;433:721–726
  9. Riesenberg K, Schlaeffer F, Katz A, et al. Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents. Br Heart J. 1995;73:14–19
  10. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French investigators of the ESSENCE trial. Circulation. 1998;98:294–299
  11. James SK, Siegbahn A, Armstrong P, et al. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non–ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. Am Heart J. 2004;147:267–274
  12. Marmur JD, Thurivakramm SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation. 1996;94:1226–1232
  13. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91:619–622
  14. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594–599
  15. Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001;86:959–972
  16. Bajaj MS, Kuppuswamy MN, Manepalli AN, et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost. 1999;82:1047–1052
  17. Lupu C, Lupu F, Dennehy U, et al. Thrombin induces the redistribution and acute release of tissue factor inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1995;15:2055–2062
  18. Golino P, Ravera A, Ragni M, et al. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation. 2003;108:2864–2869
  19. Valentin S, Nordfang O, Bregengard C, et al. Evidence that the C-terminus for tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis. 1993;4:713–720
  20. Hansen JB, Svensson B, Olsen R, et al. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost. 2000;83:937–943
  21. Li Y, Rodriguez M, Spencer FA, et al. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular tissue factor pathway release: a model for assessing intrinsic thromboresistance. J Thromb Thrombolysis. 2003;14:123–129
  22. Hansen JB, Sandset PM, Huseby KR, et al. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 1996;76:703–709
  23. Lupu C, Poulsen E, Roquefeuil S, et al. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1999;19:2251–2262
  24. Becker RC, Spencer FA, Li Y, et al. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes. J Am Coll Cardiol. 1999;34:1020–1027
  25. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111
  26. Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. J Am Coll Cardiol. 2001;37:1001–1007
  27. TRIM Study Group. A low molecular weight, selective thrombin inhibitor, inogatran vs heparin, in unstable coronary artery disease in 1,209 patients: a double-blind, randomized, dose-finding study. Eur Heart J. 1997;18:1416–1425
  28. Lauer MA, Houghtaling PL, Peterson JG, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes. Observations from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation. 2001;104:1772–1777
  29. Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost. 2001;85:824–829
  30. Brown JR, Kuter DJ. The effect of unfractionated vs low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost. 2001;85:979–985
  31. Hansen J-B, Sandset PM, Huseby KR, et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol. 1998;101:638–646
  32. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 2002;22:539–548
  33. Brown JR, Kuter DJ. The effect of unfractionated vs low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients. Thromb Haemost. 2001;85:979–985
  34. Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non–Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol. 2000;36:1507–1513
  35. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256

 Guest editor for this manuscript was Pierre Theroux, MD, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada.

PII: S0002-8703(05)00382-0

doi: 10.1016/j.ahj.2005.04.006

American Heart Journal
Volume 150, Issue 2 , Pages 189-192 , August 2005

Article Tools

* Image Usage & Resolution